Compare Enovix Corporation (ENVX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Revvity Inc — how do they compare? Enovix Corporation trades at $4.85 (market cap $1.11B), while Revvity Inc trades at $110.91 (market cap $12.42B). The key difference: Revvity Inc is far larger — about 11.2× Enovix Corporation's market cap, and Revvity Inc pays a 0.25% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ENVX | RVTY | |
|---|---|---|
Market Cap | $1.11B | $12.42B |
Sector | Technology | Technology |
52-Week High | $15.93 | $117.75 |
52-Week Low | $4.84 | $82.26 |
Enterprise Value | $1.13B | $14.91B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.855, down 4.05% today amid bearish technical signals. The company shows strong revenue growth potential with recent earnings beats but operates at a significant loss, reflected in a -499.64% net margin. Positive sentiment is driven by analyst consensus with a $12.75 price target and recent operational hires from Apple, though cash flow remains negative as production scales.
Outlook hinges on successful manufacturing ramp-up and smartphone battery qualification. High execution risk and cash burn present challenges, but leadership in silicon-anode technology offers long-term upside if commercial targets are met. Investors face volatility but potential reward from current discounted levels.
RVTY trades at $110.99, down slightly by 0.2% today, near the analyst consensus price target of $111.43. The stock shows a bullish technical trend with recent earnings beats in Q3 2025, Q4 2025, and Q1 2026. Strong profitability metrics include a gross margin of 54.32% and net income margin of 8.26%. Recent news highlights AI integration advancements and FDA clearances, supporting growth prospects.
The outlook is positive with analyst consensus leaning buy (51.72%) and no sell ratings. Key risks include margin pressure and macroeconomic headwinds affecting cash flow, which turned negative in 2025 and 2026. The upcoming Q2 2026 earnings report on August 4, 2026, will be critical for validating current growth trajectory and investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
